BR0014246A - Utilização de uma proteìna ompa de enterobactéria, ou um de seus fragmentos, associada a um peptìdeo imunogênico derivado do vìrus respiratório sincicial - Google Patents

Utilização de uma proteìna ompa de enterobactéria, ou um de seus fragmentos, associada a um peptìdeo imunogênico derivado do vìrus respiratório sincicial

Info

Publication number
BR0014246A
BR0014246A BR0014246-8A BR0014246A BR0014246A BR 0014246 A BR0014246 A BR 0014246A BR 0014246 A BR0014246 A BR 0014246A BR 0014246 A BR0014246 A BR 0014246A
Authority
BR
Brazil
Prior art keywords
peptide derived
immunogenic peptide
fragments
syncytial virus
protein
Prior art date
Application number
BR0014246-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Nathalie Corvaia
Liliane Goetsch
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of BR0014246A publication Critical patent/BR0014246A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BR0014246-8A 1999-09-23 2000-09-22 Utilização de uma proteìna ompa de enterobactéria, ou um de seus fragmentos, associada a um peptìdeo imunogênico derivado do vìrus respiratório sincicial BR0014246A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9911888A FR2798857B1 (fr) 1999-09-23 1999-09-23 Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale
PCT/FR2000/002626 WO2001021203A1 (fr) 1999-09-23 2000-09-22 Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale

Publications (1)

Publication Number Publication Date
BR0014246A true BR0014246A (pt) 2002-05-21

Family

ID=9550162

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014246-8A BR0014246A (pt) 1999-09-23 2000-09-22 Utilização de uma proteìna ompa de enterobactéria, ou um de seus fragmentos, associada a um peptìdeo imunogênico derivado do vìrus respiratório sincicial

Country Status (10)

Country Link
EP (1) EP1218029A1 (fr)
JP (1) JP2003528812A (fr)
CN (1) CN1379682A (fr)
AU (1) AU7530100A (fr)
BR (1) BR0014246A (fr)
CA (1) CA2385404A1 (fr)
FR (1) FR2798857B1 (fr)
MX (1) MXPA02003132A (fr)
WO (1) WO2001021203A1 (fr)
ZA (1) ZA200202175B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2827605B1 (fr) * 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
FR2828106A1 (fr) * 2001-08-02 2003-02-07 Pf Medicament Utilisation d'une omp d'enterobacterie de faible masse moleculaire comme porteur et/ou adjuvant
EP2487243A3 (fr) * 2005-01-07 2013-08-28 Alnylam Pharmaceuticals Inc. Modulation de l'ARNi du VRS et utilisations thérapeutiques correspondantes
JP5646620B2 (ja) * 2009-07-17 2014-12-24 インダストリー アカデミック コーポレーション ファウンデーション， ハルリム ユニバーシティー リポソームに被包されたオリゴヌクレオチド及びエピトープを含む免疫増強用組成物
KR20220119527A (ko) * 2012-08-01 2022-08-29 버베리안 노딕 에이/에스 재조합 변형된 백시니아 바이러스 앙카라(ankara) (mva) 호흡기 신시티알 바이러스(rsv) 백신
CN103243112A (zh) * 2013-05-16 2013-08-14 河北科星药业有限公司 预防大肠杆菌病的基因tsh-Ser及其制备以及利用其编码的蛋白

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1331355C (fr) * 1986-04-21 1994-08-09 Bioenterprises Pty. Ltd Immunopotentialisation
FR2726472B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin
FR2726577B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Procede d'obtention d'un peptide derive du virus respiratoire syncitial, polypeptide et bacterie l'exprimant, et leurs applications a titre de medicament
FR2766192B1 (fr) * 1997-07-17 2001-07-13 Pf Medicament Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
BR9815496A (pt) * 1997-07-18 2001-12-18 Connaught Lab Vacinas de ácido nucléico que codificam proteìna gde vìrus sincicial respiratório
FR2776521B1 (fr) * 1998-03-27 2000-12-15 Pf Medicament Utilisation de conjugues p40 actifs par voie nasale

Also Published As

Publication number Publication date
ZA200202175B (en) 2002-12-24
FR2798857B1 (fr) 2003-06-06
WO2001021203A9 (fr) 2002-05-10
CN1379682A (zh) 2002-11-13
EP1218029A1 (fr) 2002-07-03
AU7530100A (en) 2001-04-24
MXPA02003132A (es) 2002-09-30
WO2001021203A1 (fr) 2001-03-29
FR2798857A1 (fr) 2001-03-30
CA2385404A1 (fr) 2001-03-29
JP2003528812A (ja) 2003-09-30

Similar Documents

Publication Publication Date Title
CA2024916A1 (fr) Medicaments pour les troubles respiratoires comprenant le salmeterol et le propionate fluticasone
DE69818707D1 (de) Chitosan und influenza-antigen(e) enthaltende impfstoff-zubereitungen zur verabreichung durch eine mukosa
BR0011737A (pt) Vacina de poxvìrus recombinante de circovìrus de porcino
NO20030337L (no) Anvendelse av hydroksyetylrutosider i fremstilling av medikamenter til behandling av vanlig forkjolelse, virus- og/eller bakterieinfeksjon i luftveiene og/eller oyne, rhinitt og hoyfeber
BR0014155A (pt) Prevenção da miocardite, do aborto e da infecção intrauterina, associados com o circovìrus-2 porcino
YU36302A (sh) Novi tiotropiumski preparati - koji sadrže prah za inhaliranje
HUP0500558A2 (hu) Alacsony dózisú entecavir formuláció és eljárás előállítására
DE69829175D1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zubereitungen
DE69002718D1 (de) Medikamente.
ES2171440T3 (es) Composicion solida mucoadhesiva, terapeutica o higienica, para administracion por aplicacion sobre la mucosa bucal o nasal.
DE50203456D1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
AU1794601A (en) Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
ATE422364T1 (de) Multivalente immunogenische zusammensetzung, die eine rsv untereinheit zusammensetzung und ein influenzavirus präparat enthält
BR0014246A (pt) Utilização de uma proteìna ompa de enterobactéria, ou um de seus fragmentos, associada a um peptìdeo imunogênico derivado do vìrus respiratório sincicial
WO2021205026A3 (fr) Composition pharmaceutique pour le traitement d'infections et de troubles induits par un virus à adn ou à arn enveloppé
WO2003018535A3 (fr) Nouvelles aminobenzophenones
WO2004023979A3 (fr) Formulation de mucus pour surfaces de muqueuses et utilisations associees
CA2436537A1 (fr) Nouvelles compositions pharmaceutiques
ES2761613T3 (es) Barrera biológica con simeticona para su uso en el tratamiento de infecciones nasofaringotubáricas
JP2000109428A (ja) 咽頭粘膜用組成物
BR0010244A (pt) Doses mensais para tratamento de infecções por streptococcus pneumoniae
BR0105968A (pt) Medicamento natural para tratamento alternativo anti-hiv
HUP0002905A2 (hu) 2-{4-[4-(4,5-Diklór-2-metilimidazol-1-il)butil]1-1piperazinil}-5-fluorpirimidin, előállítása és gyógyászati alkalmazása
Hugues et al. A controlled, multicentre study of cefixime versus amoxicillin in the treatment of lower respiratory tract infections in adults.
PT1448184E (pt) Utilizacao de propionil l-carnitina, ou um dos seus sais farmacologicamente aceitaveis para a preparacao de um medicamento para o tratamento da doenca de la peyronie

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired